The overview

[Chart: Fortune Business Insights, Grand View Research, MarketsandMarkets, Global Market Insights, Allied, 360iResearch, Straits (2021-2026 releases). See the live document for the chart.]

Workload (from our ranking)MarketLatest sizeForecastGrowth a year
1. EU MDR and US submissionsDevice regulatory affairs outsourcing$2.1B (2024, device segment) to $4.6B (2021)$8.1B (2031)6 to 7%
1. EU MDR and US submissionsMedical device CROno current base found$14.0 to 15.1B (2030)6.4 to 9.6%
1. EU MDR and US submissionsDevice testing, inspection, and certification$3.2B (2024, TIC) to $10.6B (2023, all testing)$5.1 to 13.5B (2028 to 2030)4.9 to 8.5%
2. CAPA, complaints, and design controlsMedical device QMS software$1.2B (2025)$2.5B (2032)10.6%
2 and 4. Complaints and postmarketMedical device complaint management$8.9B (2025)$13.3 to 19.2B (2030 to 2034)about 8.8 to 8.9%
Cross-cuttingAI in regulatory affairs (all life sciences)$1.3 to 1.5B (2024 to 2025)$6.7 to 7.2B (2033 to 2034)about 18.6%

These markets are smaller than pharma’s, where clinical trial services alone are about $58 to 60 billion. Medtech spending is spread across more specialized vendors. Software and AI again grow fastest.

Regulatory outsourcing, CROs, and testing

Regulatory affairs outsourcing.

  • Global Market Insights sizes all healthcare regulatory affairs outsourcing at $7.5 billion in 2024 ($8.1 billion in 2025), reaching $15.7 billion by 2034. Medical device companies were $2.1 billion of that in 2024, growing 7.1% a year.
  • Allied Market Research gives an older, device-specific figure: $4.6 billion in 2021, reaching $8.1 billion by 2031.
  • Our reading: the EU MDR workload described in our companion article, with its new reports and longer reviews, is a likely driver of this demand.

Medical device CROs. Grand View forecasts $14.0 billion by 2030 (9% a year). Precedence (2022) forecast $15.1 billion by 2030, from $7.3 billion in 2020. We found no reliable current base-year figure.

Testing, inspection, and certification.

  • Grand View sizes the narrow medical device TIC market at $3.2 billion in 2024, reaching $5.1 billion by 2030.
  • MarketsandMarkets uses a broader testing scope: $10.6 billion in 2023, reaching $13.5 billion by 2028.

Company revenue as a reality check (2025). The large testing groups do not report medical revenue separately, so they show scale rather than device-specific size:

Company2025 revenueMedtech note
SGSCHF 6.9 billionno medical breakout
Intertek£3.4 billioncites “more demand for medical devices”; bought a medical device testing lab
UL Solutions$3.1 billionno medical breakout

Quality, complaints, postmarket, and AI

QMS software. 360iResearch puts medical device quality management software at $1.2 billion in 2025, growing 10.6% a year to $2.5 billion by 2032. The broader life sciences QMS market, mostly pharma, is about $3.7 billion (Grand View). FDA’s new QMSR, in force since February 2026, is likely to add to demand.

Supplier anchors:

  • One private QMS vendor passed $200 million in annual recurring revenue in 2025, with more than 1,250 customers.
  • One listed life sciences cloud vendor, whose products include quality software, reported $3.2 billion of total revenue. It does not report medtech separately.

Complaint management. This is the largest workload market we found that serves a single function.

  • Fortune Business Insights: $8.9 billion in 2025, reaching $19.2 billion by 2034 (8.9% a year).
  • Grand View: $13.3 billion by 2030 (8.8% a year).
  • These figures likely include services as well as software. They fit the workload data: CAPA and complaint files are among FDA’s top warning letter citations, and FDA receives more than 2 million medical device reports a year.

Medical device vigilance. Some firms publish figures of $66 to 90 billion. These are far larger than any related market and likely use a very broad scope, so we do not rely on them.

AI in regulatory affairs (all life sciences, including devices):

  • Grand View: $1.3 billion in 2024, reaching $6.7 billion by 2033 (18.6% a year).
  • Straits: $1.5 billion in 2025, reaching $7.2 billion by 2034.

It is small today but growing more than twice as fast as the outsourcing markets.

Why estimates differ

  • Scope. “Vigilance” and “testing” estimates range from narrow to very broad, which explains the very large figures some firms publish.
  • Age. Several device-specific figures date from 2020 to 2022. We mark their years.
  • Shared markets. Regulatory outsourcing and AI figures often cover pharma and devices together.
  • No company breakouts. Testing groups and software vendors do not report medtech revenue separately.

Using market data in AI and RAG

  1. Store each estimate with its firm, scope, base year, and release date.
  2. Mark figures that cover all life sciences rather than devices only.
  3. Show ranges and leave out outliers, with a note explaining why.
  4. Map each market to the workload it serves, as in the overview table.

Common mistakes

  • Using a 2020 forecast as a current market size.
  • Treating a life sciences total as a device-only figure.
  • Citing the very large vigilance estimates without checking their scope.
  • Adding markets that overlap, such as complaint management and QMS software.

Checklist

  • Two or more sources per market where available
  • Scope and base year recorded
  • Device-only and life sciences figures separated
  • Outliers flagged

How AskDona helps

AskDona sits where these markets overlap: the documents behind technical files, clinical evaluations, complaints, CAPAs, and labels. Whether the work is done in-house or by a consultant, test lab, or CRO, AskDona checks it against the rules and source records and cites the passage behind each finding.

Run a sample vendor deliverable evidence check

AskDona shows the evidence; your regulatory and quality teams decide.

Editor’s note. This article is general information, not investment advice. Market sizes are commercial research estimates with different scopes and base years; some date from 2020 to 2022 and are marked as such. Company figures come from 2025 annual results.

FAQ

How big is the medical device regulatory outsourcing market? About $2.1 billion in 2024 for device companies (Global Market Insights). Older estimates go up to $4.6 billion.

How big is the medical device CRO market? Forecasts put it at $14 to 15 billion by 2030.

How big is the complaint management market? About $8.9 billion in 2025, growing about 9% a year.

What is growing fastest? AI in regulatory affairs, at about 18.6% a year, followed by QMS software at about 10.6%.

References

All pages opened and checked by October 31, 2026.

SourceWhat it supports
Global Market Insights: Healthcare RA outsourcing$7.5B total, $2.1B device segment
Allied: Medical device RA outsourcing$4.6B (2021), $8.1B (2031)
Grand View via GII: Medical device CRO$14.0B by 2030
Precedence via BioSpace: Medical device CRO$7.3B (2020), $15.1B (2030)
Grand View via GII: Device TIC$3.2B (2024)
MarketsandMarkets: Medical device testing$10.6B (2023)
360iResearch via GII: Device QMS software$1.2B (2025)
Grand View via GII: Life sciences QMS$3.7B (2025)
Fortune Business Insights: Complaint management$8.9B (2025)
Grand View via GII: Complaint management$13.3B by 2030
Grand View via GII: AI in regulatory affairs$1.3B (2024)
Straits: AI in regulatory affairs$1.5B (2025)
UL Solutions: 2025 resultsRevenue
Intertek: 2025 resultsRevenue, medical device demand
SGS: 2025 resultsRevenue
Private QMS vendor: $200M ARRQMS vendor scale
Life sciences cloud vendor: FY2026 resultsRevenue